Akebia Therapeutics

$4.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-4.93%) Today
+$0.27 (6.67%) As of 4:17 PM EDT after-hours

Why Robinhood?

You can buy or sell AKBA and other stocks, options, ETFs, and crypto commission-free!

About AKBA

Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Read More The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Employees
325
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
481.40M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
834.05K
High Today
$4.38
Low Today
$4.03
Open Price
$4.23
Volume
795.57K
52 Week High
$10.45
52 Week Low
$3.50

Collections

AKBA News

ReutersAug 15

Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT

7

AKBA Earnings

-$0.76
-$0.42
-$0.09
$0.25
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
-$0.49 per share

Popular Stocks

More AKBA News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.